We narrowed to 88 results for: dre

#50465-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#50477-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hM4D(Gi)-mCherry (#50477). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM4D(Gi)-mCherry plasmid DNA. CaMKIIa-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

March 12, 2021

Academic Institutions and Nonprofits only

#121538-AAV5

Ready-to-use AAV5 particles produced from pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) (#121538). In addition to the viral particles, you will also receive purified pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) plasmid DNA. Synapsin-driven, HA-tagged hM4D(Gi) for neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

March 26, 2019

Academic Institutions and Nonprofits only

#50458-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-rM3D(Gs)-mCherry (#50458). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-rM3D(Gs)-mCherry plasmid DNA. hSyn-driven, Cre-dependent rM3D(Gs) receptor with an mCherry reporter for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#177673-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff DREADD Gi-mCherry (#177673). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff DREADD Gi-mCherry plasmid DNA. nEF-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition only in Cre expressing cells and not in Flp expressing cells. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#83897-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only

#83896-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#140136-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Oct. 28, 2021

Academic Institutions and Nonprofits only

#140136-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Nov. 29, 2021

Academic Institutions and Nonprofits only

#121538-AAV2

Ready-to-use AAV2 particles produced from pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) (#121538). In addition to the viral particles, you will also receive purified pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) plasmid DNA. Synapsin-driven, HA-tagged hM4D(Gi) for neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Sept. 25, 2019

Academic Institutions and Nonprofits only

#50476-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#50467-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 10, 2019

Academic Institutions and Nonprofits only

#50467-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2020

Academic Institutions and Nonprofits only

#50457-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#50469-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#121539-AAV2

Ready-to-use AAV2 particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

April 3, 2023

Academic Institutions and Nonprofits only

#50469-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#50477-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hM4D(Gi)-mCherry (#50477). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM4D(Gi)-mCherry plasmid DNA. CaMKIIa-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Dec. 18, 2024

Academic Institutions and Nonprofits only

#50475-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-hM4D(Gi)-mCherry (#50475). In addition to the viral particles, you will also receive purified pAAV-hSyn-hM4D(Gi)-mCherry plasmid DNA. hSyn-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Oct. 21, 2024

Academic Institutions and Nonprofits only

#50469-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 27, 2024

Academic Institutions and Nonprofits only